Company Abion Inc.

Equities

A203400

KR7203400007

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
8,270 ^KRW	+0.85%		+8.96%	-1.90%

2023	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI
2023	TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc.	CI

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

KRW in Million	2022	Weight	2023	Weight	Delta
Biotechnology-related Research and Development Services 100.0 %	2,507	100.0 %	1,274	100.0 %	-49.16%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	2,507	100.0 %	1,274	100.0 %	-49.16%

Managers	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	53	01/10/01
Yoon-Soo Kang DFI	Director of Finance/CFO	47	01/19/01
Joon-Young Choi COO	Chief Operating Officer	49	01/19/01
Hwa-Young Lee BRD	Director/Board Member	42	01/19/01
Do-Hyung Kim AUD	Comptroller/Controller/Auditor	51	-

Members of the board	Title	Age	Since
Eun-Hyun Jang BRD	Director/Board Member	55	-
Young-Gi Shin CEO	Chief Executive Officer	53	01/10/01
Joon-Young Choi COO	Chief Operating Officer	49	01/19/01
Moon-Chang Lee BRD	Director/Board Member	59	-
Yoon-Soo Kang DFI	Director of Finance/CFO	47	01/19/01
Hwa-Young Lee BRD	Director/Board Member	42	01/19/01
Yoon-Taek Jeong BRD	Director/Board Member	55	25/22/25
Jin-Wook Yang BRD	Director/Board Member	54	25/22/25
Geun-Chul Park BRD	Director/Board Member	68	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	22,025,993	12,739,382 ( 57.84 %)	0	57.84 %

Name	Equities	%	Valuation
TELCON RF PHARMACEUTICAL. INC. 11.39 %	2,508,381	11.39 %	12 M ₩
Young-Gi Shin 10.57 %	2,328,842	10.57 %	11 M ₩
Starquest Asset Management Co. Ltd. 2.462 %	542,340	2.462 %	3 M ₩
Young-woo Choi 1.998 %	440,000	1.998 %	2 M ₩
Young-ho Choi 1.998 %	440,000	1.998 %	2 M ₩
Kyeong-ja Moon 1.998 %	440,000	1.998 %	2 M ₩
Kyung-ah Baek 1.856 %	408,846	1.856 %	2 M ₩
NH Investment & Securities Co., Ltd. /Private Equity/ 1.695 %	373,312	1.695 %	2 M ₩
Ik-seon Choi 1.639 %	361,008	1.639 %	2 M ₩
LABGENOMICS CO., LTD. 1.117 %	245,941	1.117 %	1 M ₩

ABION, Inc.

9/F, HanWha Biz Metro Building 242 Digital-ro

08394, Seoul

http://www.abionbio.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ABION INC.	-1.90%	132M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs